Combined inhibition of CDK4/6 and AKT is highly active against the luminal androgen receptor (LAR) subtype of triple negative breast cancer (TNBC)

被引：1
|
作者：
Chica-Parrado, Maria del Rosario
Kin, Gun Min
Lin, Chang-Ching
Lee, Kyung-Min
Napolitano, Fabiana
Ye, Dan
Bikorimana, Emmanuel
Mendirata, Saurabh
Hanker, Ariella
Arteaga, Carlos L.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-5483
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5483
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?
    Mavratzas, Athanasios
    Marme, Frederik
    BREAST CARE, 2021, 16 (02) : 115 - 128
  • [42] Dual inhibition of CDK4/6 and IL-6 pathways as a novel therapeutic approach for triple-negative breast cancer cells
    Caroland, Kailey
    Shi, Changyou
    Lo, Hui-Wen
    Lin, Jiayuh
    CANCER RESEARCH, 2024, 84 (06)
  • [43] Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 Inhibition
    Demirsoy, Seyma
    Tran, Ha
    Liu, Joseph
    Li, Yunzhan
    Yang, Shengyu
    Aregawi, Dawit
    Glantz, Michael J.
    Jacob, Naduparambil K.
    Walter, Vonn
    Schell, Todd D.
    Olmez, Inan
    CANCERS, 2024, 16 (12)
  • [44] Combined inhibition of CDK2 and CDK4/6 overcomes acquired resistance to CDK4/6 inhibitors in breast cancer via RB-independent pathway
    Pandey, Kamal
    CANCER RESEARCH, 2020, 80 (16)
  • [45] Efficacy of combined CDK4/6 inhibitor and PARP inhibitor in the treatment of BRCA1 mutant triple negative breast cancer
    Zhu, Xiuzhi
    Chen, Li
    Wang, Zhonghua
    CANCER RESEARCH, 2021, 81 (04)
  • [46] Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer
    Peng, Wen -Ting
    Jin, Xi
    Xu, Xiao-En
    Yang, Yun-Song
    Ma, Ding
    Shao, Zhi-Ming
    Jiang, Yi-Zhou
    CANCER RESEARCH, 2023, 83 (10) : 1711 - 1724
  • [47] Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
    Pandey, Kamal
    Park, Nahee
    Park, Kyung-Soon
    Hur, Jin
    Cho, Yong Bin
    Kang, Minsil
    An, Hee-Jung
    Kim, Sewha
    Hwang, Sohyun
    Moon, Yong Wha
    CANCERS, 2020, 12 (12) : 1 - 17
  • [48] A computational model of the mechanisms of action of combined endocrine therapy and CDK4/6 inhibition predicts outcome in patients with Luminal B breast cancer
    Schmiester, Leonard
    Braso-Maristany, Fara
    Kristensen, Vessela
    Frigessi, Arnoldo
    Prat, Aleix
    Kohn-Luque, Alvaro
    CANCER RESEARCH, 2024, 84 (09)
  • [49] AKT inhibition in combination with endocrine therapy and a CDK4/6 inhibitor (CDK4/6i) in patients with hormone receptor positive (HR+)/HER2 negative metastatic breast cancer (MBC) and prior CDK4/6i exposure: A translational investigation
    Wander, Seth A.
    Micalizzi, Douglas S.
    Dubash, Taronish
    Juric, Dejan
    Spring, Laura M.
    Vidula, Neelima
    Keenan, Jennifer
    Beeler, Maureen
    Viscosi, Elene
    Che, Dante
    Fisher, Elizabeth L.
    Hepp, Rachel A.
    Moy, Beverly
    Isakoff, Steven J.
    Ellisen, Leif W.
    Supko, Jeffrey G.
    Maheswaran, Shyamala
    Haber, Daniel A.
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [50] Mechanistic exploration of combined CDK4/6 and ER inhibition in ER-positive breast cancer
    Lee, Nathan V.
    Yuan, Jing
    Eisele, Koleen
    Cao, Joan Q.
    Painter, Cory L.
    Chionis, John
    Liu, Chaoting
    Shields, David J.
    Kan, Julie L. C.
    Arndt, Kim
    VanArsdale, Todd
    CANCER RESEARCH, 2014, 74 (19)
12345